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Abstract: Introduction: Evidence on the management of chondral defects of the patella arises from
studies in which the patellofemoral joint was treated together with the femorotibial joint and primary
and revision settings. Furthermore, the superiority of Autologous Matrix Induced Chondrogenesis
(AMIC) over microfractures (MFx) for patellar chondral defects is uncertain. Therefore, the present
study compared primary isolated AMIC versus MFx for focal unipolar chondral defects of the patellar
facet joints at midterm follow-up. Methods: Patients undergoing AMIC or isolated MFx surgery
for borderline-sized focal unipolar chondral defects of the patellar facet joints were followed at our
institution. All surgeries were performed in the same fashion by experienced surgeons. A parapatellar
arthrotomy was adopted in all surgeries. The outcomes of interest were: Visual Analogic Scale (VAS),
Tegner Activity Scale, International Knee Documentation Committee (IKDC), and the Lysholm scores.
The Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) was assessed by a
blinded radiologist, who had not been involved in the clinical management of the patients. Results:
38 patients were enrolled in the present study: 27 underwent AMIC, and 11 MFx. The mean follow-up
was 45.1 months. The mean age of the patients at baseline was 34.5 years. The mean size of the
defect was 2.6 cm2. The MFx cohort experienced a shorter length of the hospitalization (P = 0.008).
There was no difference in terms of follow-up and previous symptoms duration, mean age, sex, side,
defect size, and BMI. At last follow-up, the AMIC cohort reported greater IKDC (P = 0.01), Lysholm
(P = 0.009), and Tegner (P = 0.02), along with a low rate of failure (P = 0.02). VAS was lower in the
AMIC group (P = 0.002). No difference was found in the MOCART score (P = 0.09), rates of revision
(P = 0.06), and arthroplasty (P = 0.2). Conclusion: The AMIC procedure achieves greater IKDC and
Lysholm score, and a significant reduction of the VAS score in the management of patellar chondral
defects. The Tegner scale demonstrated greater activity after AMIC procedure. Finally, the AMIC
group evidenced a lower rate of failure. Similarity was found on MOCART score, rates of revision,
and arthroplasty between the two procedures.
Keywords: knee; patella; autologous matrix induced chondrogenesis; AMIC; microfractures; chon-
dral defects; management
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1. Introduction
Symptomatic focal chondral defects of the patella are common [1,2]. If left untreated,
they can lead to early osteoarthritis [3]. Several surgical approaches have been proposed to
manage chondral defects [4–9]. Microfractures (MFx) is cost-effective and has been largely
used to manage smaller chondral defects [4,5]. Autologous chondrocyte implantation
(ACI) techniques evolved from the periosteal patch (pACI), to chondral patch (cACI), to
third generation procedures named matrix-induced ACI (mACI) [2,10–12]. Irrespective of
the generation, ACI requires harvesting, external chondrocyte expansion, and a second
stage surgery for re-implantation [13–15]. The superiority of ACI compared to MFx is
still controversial [16–18]. Autologous Matrix-Induced Chondrogenesis (AMIC) avoids
cartilage harvest and external expansion and is performed in a single surgical session [19,20].
Differently to ACI, which requires expanded autologous chondrocytes, AMIC exploits
the potential of bone marrow-derived mesenchymal stem cells [21,22]. Isolated AMIC
for chondral defects of the patella joint surface in a primary setting has been poorly
investigated. Evidence on the management of chondral defects of the patella mainly arises
from studies in which the patellofemoral joint was treated together with the femorotibial
joint, and primary and revision settings were mixed [23–26]. Especially for borderline sized
defects, the superiority of AMIC with respect to MFx for patellar defects is uncertain. The
present study compared primary isolated AMIC versus MFx for focal unipolar chondral
defects of the patellar facet joints at midterm follow-up.
2. Material and Methods
2.1. Patients Recruitment
The present study was conducted according to the Consolidated Standards of Report-
ing Trials: the CONSORT statement [27]. This study was conducted in the Department
of Orthopaedic Surgery of the RWTH University Hospital of Aachen between 2012 and
2020. All patients undergoing primary isolated AMIC or MFx for focal unipolar chondral
defects of the patellar facet joints were consecutively enrolled. The inclusion criteria were:
(1) symptomatic patellar chondral defect, (2) isolated focal defect sized 1.5 to 3.5 cm2, and
(3) MRI evidence (Figure 1). The exclusion criteria were: (1) bilateral lesions, (2) multifocal
lesions, (2) previous knee surgeries, (5) patellofemoral instability or history of dislocations,
(6) lateral patellar compression syndrome, (7) any bone deformity, (8) radiographic evi-
dence of osteoarthritis, and (7) any other relevant pathology that can influence the study.
Suitable patients were asked to participate in this study pre-operatively. Patients were
informed about pros and cons of both techniques, and they were free to choose between
AMIC or MFx. In 2020, all patients were invited to participate in the present study, which
was approved and registered by the ethics committee of the RWTH University of Aachen
(project ID EK 438-20) and was performed according to the principles expressed in the
Declaration of Helsinki. All patients were able to understand the nature of their treatment
and provided written consent to use their clinical and imaging data for research purposes.
2.2. Surgical Technique
All the surgeries were performed in the same fashion by two experienced surgeons
according to a previous report [28]. Briefly, preliminary arthroscopy was performed
through traditional anteromedial and anterolateral portals. Debridement and curettage of
the non-viable tissues surrounding the lesion were performed. MFx to a depth of 4 mm
were performed using a 65◦ and 90◦ pick. In those patients who underwent AMIC, a mini
medial parapatellar approach was performed. The perforation of the subchondral bone
was performed with a 40◦ pick or a 1.2/1.4 mm Kischer wire under constant irrigation. An
aluminum template was trimmed according to the defect. A type I/III porcine resorbable
collagen membrane was used in all procedures (Chondro-Gide, Geistlich Pharma AG,
Wolhusen, Switzerland). The membrane was trimmed according to the aluminum template
to slightly undersize the defect to avoid displacement. The membrane was hydrated in a
saline solution and placed into the lesion and attached with fibrin glue. The stability of the
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membrane was checked by repeatedly flexing and extending the knee. The rehabilitation
process was performed according to our previous study [29].
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Figure 1. MRI of a focal chondral defect of the patella.
2.3. Outcomes of Interest
On admission, the following data were recorded: age, gender, side, area of defect, BMI
(Kg/m2), symptoms duration prior to surgery, and length of hospital stay. The primary
outcomes of interest were to compare clinical findings using patient reported outcomes
measures (PROMs) and complications of b th grou s. The secondary outcomes of inter-
est were t compare MRI findings accordi g t the Magnetic Resonance Observation of
Cartilage Re ir Tissue (MOCART) score [30]. At last follow-up, patients performed ind -
pendently th following scores: Visual Analog Scale (VAS) [31], Tegner Activity Scale [32],
International Knee Documentation C mmittee (IKDC) [33], and the Lysholm [34] scores.
Dat concerning th rate of complications (failure, revision, arthroplasty, delamination, hy-
pertrophy) and additional procedures were al o collected. Failure was defined as persistent
ain that affected negatively the quality of life and limited he participation to recreational
activities. The MOCART score was performed by a blind radiologist, who had not been
involved in the clinical management of the patients.
2.4. Statistical Analysis
All statistical analyses were performed using the software IBM SPSS version 25.
Continuous data were analysed using the mean difference (MD), while dichotomic data
with odd ratio (OR) effect measures for parametric data. The T-test and χ2 tests were
performed, respectively, with values of P < 0.05 considered statistically significant. The
confidence interval (CI) was set at 95% in all comparisons.
3. Results
3.1. Recruitment Process
A total of 76 patients were initially screened. Of them, 25 were not eligible: kissing
lesions (N = 1), bilateral lesions (N = 1), multiple lesions (N = 5), previous knee surgeries
(N = 14), metabolic bone disease (N = 1), and patellofemoral instability or history of
dislocations (N = 3). Fifty-one patients were available and operated: 32 underwent AMIC
and 19 microfractures. At last follow-up, five patients who had undergone AMIC and eight
microfractures were not available. Eventually, 38 patients were enrolled in the present
Life 2021, 11, 141 4 of 10
study: 27 underwent AMIC, and 11 MFx. The diagram of the recruitment process is shown
in Figure 2.
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3.2. Patients Demographics
The mean length of the follow-up was 45.1 months. The mean age of the patients at
baseline was 34.5 years. The mean size of the defect was 2.6 cm2 (1.1 to 3.0). Fifty percent
(19 of 38 patients) were women, and in 61% (23 of 38) of patients the right side was affected.
The MFx cohort evidenced a shorter length of hospitalization (P = 0.008). There was no
difference in terms of follow-up and previous symptoms duration, mean age, sex, side,
defect size, and BMI. Demographic data of the patients are shown in Table 1.
Table 1. Demographic data of the patients (n.s.: not significant).
Endpoint AMIC (n = 27) MFx (n = 11) P
Follow-up (months) 45.1 ± 22.9 49.1 ± 33.7 n.s.
Mean age 35.8 ± 14.5 31.4 ± 11.3 n.s.
Sex (female) 48% (13 of 27) 55% (6 of 11) n.s.
Side (leg) 59% (16 of 27) 58% (7 of 11) n.s.
Side (joint)
Medial facet 48% (13 of 27) 72% (8 of 27)
Lateral facet 52% (14 of 27) 28% (3 of 27)
Symptoms duration (months) 68.7 ± 78.4 71.4 ± 83.3 n.s.
Hospitalization (days) 2.8 ± 1.1 1.8 ± 0.7 0.008
Area of defect (cm2) 2.7 ± 1.6 2.5 ± 0.6 n.s.
BMI (kg/m2) 26.9 ± 5.2 25.1 ± 3.4 n.s.
3.3. Outcomes of Interest
At last follow-up, the AMIC cohort reported greater IKDC (P = 0.01), Lysholm
(P = 0.009), and Tegner (P = 0.02). VAS was lower in the AMIC group (P = 0.002). No
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difference was found in the MOCART score (P = 0.09). These results are shown in greater
detail in Table 2.
Table 2. Main results at last follow-up.
Endpoint AMIC (n = 27) MFx (n = 11) 95% CI MD P
IKDC 89.3 ± 16.4 74.9 ± 11.5 3.375 to 25.425 14.4 0.01
Lysholm 89.6 ± 10.5 78.1 ± 14.0 3.100 to 19.900 11.5 0.009
MOCART 70.0 ± 17.3 58.8 ± 18.9 1.683 to 24.083 11.2 0.09
VAS (0–10) 1.3 ± 0.7 2.5 ± 1.5 1.918 to 0.482 1.2 0.002
Tegner 5.0 ± 1.7 3.5 ± 1.9 0.225 to 2.775 1.5 0.02
3.4. Complication
The AMIC group reported a lower rate of failure (P = 0.02). No difference was found in
the rates of revision (P = 0.06) and arthroplasty (P = 0.2). No delamination or hypertrophy
were reported at the last follow-up. These results are shown in greater detail in Table 3.
Table 3. Complications: rate of revision, arthroplasty, and failure.
Endpoint AMIC (n = 27) MFx (n = 11) OR 95% CI P
Revision 4% (1 of 27) 27% (3 of 11) 0.103 0.0093 to 1.1282 0.06
Arthroplasty 0% (0 of 27) 9% (1 of 11) 0.1273 0.0048 to 3.3780 0.2
Failure 4% (1 of 27) 36% (4 of 11) 0.067 0.0065 to 0.7022 0.02
4. Discussion
According to the main findings of the present study, for patellar chondral defects,
AMIC achieves greater IKDC and Lysholm score, along with a significant reduction of the
VAS score. The Tegner scale demonstrated greater sporting activity after AMIC. Finally,
the patients in the AMIC group experienced lower rate of failure. Similarity was found on
MOCART score, rates of revision, and arthroplasty between the two procedures.
Up to 60% of patients undergoing knee arthroscopy evidence chondral defect [35]. Of
them, up to 37% are located in the patellar facets [36–39]. Previous studies concerning pa-
tients treated for patellar chondral defects with autologous chondrocyte implantation (ACI)
reported acceptable clinical results [35,40–47]. However, in these studies the patellofemoral
joint was mainly treated along with the femorotibial joint, and primary and revision settings
were not considered separately [23–26]. Tradati et al. [48] recently published a retrospec-
tive survey including 14 patients who underwent primary AMIC for isolated patellar
defects. At a mean of 68.2 months follow-up, 78% of patients rated their outcomes as
excellent [48]. They evidenced a statistically significant increase of the Tegner, Kuajala, and
IKDC scores [48]. We were unable to identify other studies which compared AMIC vs. MFx
for primary isolated chondral defect of the patella. MFx is suggested for chondral defect
sized up to 2.5 cm2, while AMIC has been proposed for bigger defects [5,19–22,49–52]. The
present cohort of patients had a mean size of 2.6 cm2, which can be considered borderline.
The choice between AMIC rather than MFx in these patients can be questionable. MFx
requires shorter surgical duration, can be performed arthroscopically, and allows quicker
recovery. These features make MFx of special interest, also in patients with borderline size
area of the defect. However, this study demonstrated that AMIC can be preferred over MFx
for patients with a mean defect size of 2.6 cm2. The resorbable membrane we employed
in all surgeries (ChondroGide) promotes the formation of the blood clot, which is rich in
bone marrow-derived mesenchymal stem cells [24]. The bilayer structure of the membrane
allows migration and proliferation of cells on its internal porous side, providing protection
from the knee cavity thought its external compact layer.
The patellofemoral joint is complex, with intricate architecture and biomechanics. Chon-
dral defects of the patella are often secondary to malalignment and instability syndromes,
which make their treatment very challenging [53,54]. In patients with patellar chondral
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defects, pathoanatomical tissue morphology predisposing to patellofemoral instability (PFI)
must be investigated [55,56]. Chondral defects are common in patients who experienced
a patellar dislocation, [57–62]. Up to 96% of patients after patellar dislocation experience
chondral damages [63–66]. Surgeons must be aware of previous patellar dislocations or
potential subluxations. Evaluation of possible varus or valgus deformity and of the result
of the apprehension test are mandatory [67,68]. Trochlear dysplasia, Install-Salvati ratio
ranging from 1.0 and 1.2, and tibial tubercle-trochlear groove (TT-TG) greater than 22 mm
also have been evaluated [69,70]. Another cause of persistent pain and possible chondral
damage is the lateral patellar compression syndrome (LPCS) [71,72]. LPCS presents short-
ened and tightened lateral retinacular combined with lateral patellar tilt, with overload
of the lateral patellar articular compartment and patellar mal-tracking [73–75]. Isolated
lateral retinacular release or lateral retinacular lengthening are indicated for LPCS [76–82],
restoring patellar tracking, and preserving the surfaces from further degeneration [83,84].
Further, femoral anteversion, generalized ligament laxity, and patellar hypermotility may
represent other underlying causes of chondral defect [85,86] and should also be evaluated
before planning surgery. It is important during clinical examination to evaluate these afore-
mentioned risk factors. Indeed, for these patients, it would be recommended to combine
AMIC with proximal or a distal realignment procedure to address the underlying cause of
chondral damage.
This study has several limitations. Patients were not randomised and not blinded
to the treatment received. The limited number of the patients included in the present
investigation may limit the ability to detect uncommon complications. The 13 patients
who did not attend the last follow-up were contacted telephonically and declared them-
selves satisfied but unavailable to attend for assessment for geographical reasons. Studies
involving larger population and longer follow-ups are required. In the present study, the
histological features of cartilage regeneration were not evaluated and the morphological
appearance was assessed qualitatively through the MOCART score. However, the quality
of the morphological assessment of the MOCART score is controversial. Previous studies
evidenced that its potential to predict clinical outcome is limited [87,88]. The strict eligi-
bility criteria, along with the good comparability between the two groups are however
important strengths of this study. Experienced surgeons performed the procedures in a
standardized fashion, with no preference of one over the other technique. Postoperative
cares and rehabilitation protocols were highly standardized, thus representing further
important strengths of the present study.
5. Conclusions
AMIC procedure achieves greater IKDC and Lysholm score, along with a significant
reduction of the VAS score as management of patellar chondral defects. The Tegner scale
demonstrated greater activity after AMIC procedure. Finally, the AMIC group evidenced
lower rate of failure. Similarity was found on MOCART score, rates of revision, and
arthroplasty between AMIC and MFx.
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